세계의 비낭포성 섬유증 기관지확장증 시장 보고서(2025년)

Non-cystic fibrosis bronchiectasis is a persistent condition marked by permanent widening and abnormality of the airways (bronchi) in the lungs. This results from recurrent inflammation and infections, which weaken and damage the walls of the bronchial tubes. Symptoms include mucus buildup, chronic coughing, breathlessness, and frequent respiratory infections. Treatment typically focuses on symptom management, preventing flare-ups, and addressing underlying factors such as bacterial infections or immune system dysfunction.

Diagnosis of non-cystic fibrosis bronchiectasis involves various methods including computed tomography (CT) scans, bronchoscopies, chest X-rays, lung function tests, sputum culture, and blood tests. CT scans provide detailed lung images that help in diagnosing bronchiectasis by revealing the extent and location of lung damage. Treatment options are categorized into surgical interventions, physiotherapy, vaccinations, airway pharmacotherapy, antibiotics, and others. These treatments are utilized across different healthcare settings such as hospitals, clinics, and ambulatory care centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The non-cystic fibrosis bronchiectasis market research report is one of a series of new reports from the business research company that provides non-cystic fibrosis bronchiectasis market statistics, including non-cystic fibrosis bronchiectasis industry global market size, regional shares, competitors with an non-cystic fibrosis bronchiectasis market share, detailed non-cystic fibrosis bronchiectasis market segments, market trends and opportunities, and any further data you may need to thrive in the non-cystic fibrosis bronchiectasis industry. This non-cystic fibrosis bronchiectasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-cystic fibrosis bronchiectasis market size has grown strongly in recent years. It will grow from $3.5 billion in 2024 to $3.7 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to rising incidence and prevalence, advances in diagnostic technologies, growing geriatric population, government support and funding, improved healthcare infrastructure, increased diagnosis awareness, rising geriatric population, environmental exposure.

The non-cystic fibrosis bronchiectasis market size is expected to see strong growth in the next few years. It will grow to $4.68 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to advances in personalized medicine, the emergence of new biomarkers, increased investment in respiratory medicine, growing research and development, public health initiatives, the global aging population, and the development of targeted therapies. Major trends in the forecast period include digital health solutions, a focus on targeted therapies, the integration of AI and machine learning, a shift towards home-based care, patient-centric approaches, and the growth of mobile health (mHealth) solutions.

The forecast of 6.1% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of inhaled mucolytic therapies by inflating prices of nebulizers and dry powder inhalers developed in the Netherlands and Canada, resulting in reduced respiratory therapy adherence and higher pulmonology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The non-cystic fibrosis bronchiectasis market is poised for growth due to the increasing incidence of respiratory diseases. These diseases encompass various conditions affecting lung and respiratory function, exacerbated by rising environmental pollution, both outdoors and indoors, such as tobacco smoke. The uptick in respiratory infections presents opportunities for advancing the understanding, diagnosis, and management of non-cystic fibrosis bronchiectasis through targeted interventions and public health initiatives. Recent data from a June 2023 report by the UK's Office for Health Improvement and Disparities highlighted a significant rise in scarlet fever Group A Streptococcus bacteria notifications during the 2022-2023 season in England, underscoring the escalating trend in respiratory illnesses. This trend underscores the anticipated growth in the non-cystic fibrosis bronchiectasis market.

Leading companies in the non-cystic fibrosis bronchiectasis market are increasingly adopting personalized medicine strategies, particularly through innovations such as nebulization solutions, to enhance the efficiency of drug delivery and improve patient adherence. Nebulization technologies represent a cutting-edge approach for precise administration of respiratory medications, thereby boosting treatment adherence and overall therapeutic outcomes. For example, in April 2022, Zambon S.P.A., a prominent pharmaceutical firm based in Italy, secured a designation from the US FDA for CMS I-neb therapy aimed at patients suffering from non-cystic fibrosis bronchiectasis (NCFB). This therapy is investigational and potentially revolutionary as an inhaled treatment for adult NCFB patients infected with P. aeruginosa, a significant milestone in advancing treatment options for this chronic and progressive respiratory condition. The breakthrough designation underscores the accelerated development and regulatory review pathway for CMS I-neb in NCFB.

In November 2023, Chiesi Farmaceutici SpA, an Italian pharmaceutical company, announced a partnership with Haisco Pharmaceutical Group Co., Ltd. This collaboration focuses on Haisco's commercialization of Chiesi's investigational bronchiectasis drug in China. Haisco will provide financial and logistical support to facilitate regulatory approval, marketing, and distribution efforts necessary for introducing the bronchiectasis treatment to the Chinese market. Haisco Pharmaceutical Group Co. Ltd., based in China, specializes in developing treatments for respiratory diseases, including bronchiectasis.

Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc, Teva Pharmaceutical Industries Ltd, Vertex Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr Reddy's Laboratories Ltd, Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc, Insmed Incorporated, Genentech, Zydus Cadila, Santhera Pharmaceuticals, TSRL Inc

North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2024. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-cystic fibrosis bronchiectasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-cystic fibrosis bronchiectasis market consists of revenues earned by entities by providing services such as diagnostic imaging, pulmonary function testing, medical consultations, home healthcare, pulmonary rehabilitation, and management of chronic respiratory infections through pharmaceutical treatments and advanced therapeutic technologies. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-cystic fibrosis bronchiectasis market also includes sales of antibiotics, bronchodilators, mucolytics, inhalers, nebulizers, airway clearance devices, and respiratory monitoring devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Cystic Fibrosis Bronchiectasis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-cystic fibrosis bronchiectasis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-cystic fibrosis bronchiectasis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-cystic fibrosis bronchiectasis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Diagnosis: Computed Tomography (CT) Scan; Bronchoscopy; Chest X Ray; Lung Function; Sputum Culture Test; Blood Tests; Other Diagnosis Types
• 2) By Treatment: Surgery; Physiotherapy; Vaccination; Airway Pharmacotherapy; Antibiotics; Other Treatments
• 3) By End Use: Hospitals And Clinics; Ambulatory Care Centers; Other End Uses
• Subsegments:
• 1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT); Standard CT
• 2) By Bronchoscopy: Flexible Bronchoscopy; Rigid Bronchoscopy
• 3) By Chest X-Ray: Standard Chest X-Ray; Digital Chest X-Ray
• 4) By Lung Function: Spirometry; Peak Flow Measurement
• 5) By Sputum Culture Test: Bacterial Culture; Fungal Culture; Viral Culture
• 6) By Blood Tests: Complete Blood Count (CBC); C-Reactive Protein (CRP); Immunoglobulin Levels
• 7) By Other Diagnosis Types: Sweat Test; Genetic Testing; Exhaled Nitric Oxide Test
• Companies Mentioned: Pfizer Inc.; F Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; Sanofi SA; Bristol-Myers Squibb Company; AstraZeneca plc; Abbott Laboratories; Novartis AG; GlaxoSmithKline plc (GSK); Boehringer Ingelheim International GmbH; Viatris Inc; Teva Pharmaceutical Industries Ltd; Vertex Pharmaceuticals; Sun Pharmaceutical Industries Ltd; Aurobindo Pharma Ltd; Dr Reddy's Laboratories Ltd; Chiesi Farmaceutici SpA; Lupin Limited; Zambon Company SpA; Sunovion Pharmaceuticals Inc; Insmed Incorporated; Genentech; Zydus Cadila; Santhera Pharmaceuticals; TSRL Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Cystic Fibrosis Bronchiectasis Market Characteristics

3. Non-Cystic Fibrosis Bronchiectasis Market Trends And Strategies

4. Non-Cystic Fibrosis Bronchiectasis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Non-Cystic Fibrosis Bronchiectasis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Non-Cystic Fibrosis Bronchiectasis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Non-Cystic Fibrosis Bronchiectasis Market Growth Rate Analysis
• 5.4. Global Non-Cystic Fibrosis Bronchiectasis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Non-Cystic Fibrosis Bronchiectasis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Non-Cystic Fibrosis Bronchiectasis Total Addressable Market (TAM)

6. Non-Cystic Fibrosis Bronchiectasis Market Segmentation

• 6.1. Global Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Computed Tomography (CT) Scan
• Bronchoscopy
• Chest X Ray
• Lung Function
• Sputum Culture Test
• Blood Tests
• Other Diagnosis Types
• 6.2. Global Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Physiotherapy
• Vaccination
• Airway Pharmacotherapy
• Antibiotics
• Other Treatments
• 6.3. Global Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Ambulatory Care Centers
• Other End Uses
• 6.4. Global Non-Cystic Fibrosis Bronchiectasis Market, Sub-Segmentation Of Computed Tomography (CT) Scan, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• High-Resolution CT (HRCT)
• Standard CT
• 6.5. Global Non-Cystic Fibrosis Bronchiectasis Market, Sub-Segmentation Of Bronchoscopy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Flexible Bronchoscopy
• Rigid Bronchoscopy
• 6.6. Global Non-Cystic Fibrosis Bronchiectasis Market, Sub-Segmentation Of Chest X-Ray, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Chest X-Ray
• Digital Chest X-Ray
• 6.7. Global Non-Cystic Fibrosis Bronchiectasis Market, Sub-Segmentation Of Lung Function, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Spirometry
• Peak Flow Measurement
• 6.8. Global Non-Cystic Fibrosis Bronchiectasis Market, Sub-Segmentation Of Sputum Culture Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bacterial Culture
• Fungal Culture
• Viral Culture
• 6.9. Global Non-Cystic Fibrosis Bronchiectasis Market, Sub-Segmentation Of Blood Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Complete Blood Count (CBC)
• C-Reactive Protein (CRP)
• Immunoglobulin Levels
• 6.10. Global Non-Cystic Fibrosis Bronchiectasis Market, Sub-Segmentation Of Other Diagnosis Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sweat Test
• Genetic Testing
• Exhaled Nitric Oxide Test

7. Non-Cystic Fibrosis Bronchiectasis Market Regional And Country Analysis

• 7.1. Global Non-Cystic Fibrosis Bronchiectasis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Non-Cystic Fibrosis Bronchiectasis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Cystic Fibrosis Bronchiectasis Market

• 8.1. Asia-Pacific Non-Cystic Fibrosis Bronchiectasis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Cystic Fibrosis Bronchiectasis Market

• 9.1. China Non-Cystic Fibrosis Bronchiectasis Market Overview
• 9.2. China Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Cystic Fibrosis Bronchiectasis Market

• 10.1. India Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Cystic Fibrosis Bronchiectasis Market

• 11.1. Japan Non-Cystic Fibrosis Bronchiectasis Market Overview
• 11.2. Japan Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Cystic Fibrosis Bronchiectasis Market

• 12.1. Australia Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Cystic Fibrosis Bronchiectasis Market

• 13.1. Indonesia Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Cystic Fibrosis Bronchiectasis Market

• 14.1. South Korea Non-Cystic Fibrosis Bronchiectasis Market Overview
• 14.2. South Korea Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Cystic Fibrosis Bronchiectasis Market

• 15.1. Western Europe Non-Cystic Fibrosis Bronchiectasis Market Overview
• 15.2. Western Europe Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Cystic Fibrosis Bronchiectasis Market

• 16.1. UK Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Cystic Fibrosis Bronchiectasis Market

• 17.1. Germany Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Cystic Fibrosis Bronchiectasis Market

• 18.1. France Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Cystic Fibrosis Bronchiectasis Market

• 19.1. Italy Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Cystic Fibrosis Bronchiectasis Market

• 20.1. Spain Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Cystic Fibrosis Bronchiectasis Market

• 21.1. Eastern Europe Non-Cystic Fibrosis Bronchiectasis Market Overview
• 21.2. Eastern Europe Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Cystic Fibrosis Bronchiectasis Market

• 22.1. Russia Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Cystic Fibrosis Bronchiectasis Market

• 23.1. North America Non-Cystic Fibrosis Bronchiectasis Market Overview
• 23.2. North America Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Cystic Fibrosis Bronchiectasis Market

• 24.1. USA Non-Cystic Fibrosis Bronchiectasis Market Overview
• 24.2. USA Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Cystic Fibrosis Bronchiectasis Market

• 25.1. Canada Non-Cystic Fibrosis Bronchiectasis Market Overview
• 25.2. Canada Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Cystic Fibrosis Bronchiectasis Market

• 26.1. South America Non-Cystic Fibrosis Bronchiectasis Market Overview
• 26.2. South America Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Cystic Fibrosis Bronchiectasis Market

• 27.1. Brazil Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Cystic Fibrosis Bronchiectasis Market

• 28.1. Middle East Non-Cystic Fibrosis Bronchiectasis Market Overview
• 28.2. Middle East Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Cystic Fibrosis Bronchiectasis Market

• 29.1. Africa Non-Cystic Fibrosis Bronchiectasis Market Overview
• 29.2. Africa Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Non-Cystic Fibrosis Bronchiectasis Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Cystic Fibrosis Bronchiectasis Market Competitive Landscape And Company Profiles

• 30.1. Non-Cystic Fibrosis Bronchiectasis Market Competitive Landscape
• 30.2. Non-Cystic Fibrosis Bronchiectasis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Non-Cystic Fibrosis Bronchiectasis Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca plc
• 31.3. Abbott Laboratories
• 31.4. Novartis AG
• 31.5. GlaxoSmithKline plc (GSK)
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Viatris Inc.
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Vertex Pharmaceuticals
• 31.10. Sun Pharmaceutical Industries Ltd.
• 31.11. Aurobindo Pharma Ltd.
• 31.12. Dr. Reddy's Laboratories Ltd.
• 31.13. Chiesi Farmaceutici SpA
• 31.14. Lupin Limited
• 31.15. Zambon Company SpA

32. Global Non-Cystic Fibrosis Bronchiectasis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Cystic Fibrosis Bronchiectasis Market

34. Recent Developments In The Non-Cystic Fibrosis Bronchiectasis Market

35. Non-Cystic Fibrosis Bronchiectasis Market High Potential Countries, Segments and Strategies

• 35.1 Non-Cystic Fibrosis Bronchiectasis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Non-Cystic Fibrosis Bronchiectasis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Non-Cystic Fibrosis Bronchiectasis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer